Effect of Prophylactic Versus Preemptive Lamivudine Treatment and Tenofovir on HBsAg (+) Kidney Transplant Recipients

Ruhi C., SÜLEYMANLAR İ., KOÇAK H., Dinckan A., Ersoy F., SÜLEYMANLAR G.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, cilt.13, sa.1, ss.35-40, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.6002/ect.2013.0280
  • Dergi Adı: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.35-40
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives: Chronic hepatitis B virus infection remains a clinical problem for HBsAg (+) kidney transplant recipients. Lamivudine is the approved treatment; however, there are contrary views about optimal initiation. In case of resistance, novel nucleoside analogs should be considered but experience is limited.